Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247275532> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2247275532 endingPage "2514" @default.
- W2247275532 startingPage "2514" @default.
- W2247275532 abstract "2514 Background: Epidermal growth factor (EGF) plays an important role in the regulation of tumor growth. Our approach consists of active immunization with human recombinant EGF coupled to a carrier protein and adjuvanted in Montanide to induce EGF deprivation. Here we report the preliminary results of a randomized Phase II trial designed to test the efficacy of the EGF cancer vaccine in stage IIIb/IV NSCLC patients. Methods: Two groups of 40 unresectable NSCLC patients were compared. All patients received first line chemotherapy and then were randomized to receive the EGF cancer vaccine (group 1) or best supportive care (group 2). Patients were vaccinated on days 0, 7, 14, 21, 51 and then monthly. Anti-EGF antibody titers and EGF concentration ([EGF]) in sera were measured. Results: Fifty patients have been included in the trial (25 vaccinated and 25 controls). Seventy (70) % of the vaccinated patients have shown seroconversion, defined as at least 2X the original antibody titer while 40 % of controls have shown a 2X increase of the natural anti-EGF antibody titers in the follow-up time. However, 50% of the vaccinated subjects developed a good antibody response (GAR), defined at least 4 times above baseline and 1:4000 titer while none of the controls did. The geometric mean of maximal antibody titers was 1: 3500 for group 1 and 1:462 for Group 2. Mean minimal [EGF] was 20 pg/ml for group 1 and 60 pg/ml for group 2. A significant increase in survival was obtained for GAR patients as compared with poor responders. A trend to increase in survival was observed for group 1 (median 8.47 months) as compared with group 2 (median 5.47 months). Conclusions: Preliminary results from a randomized Phase II trial corroborate the immunogenicity and safety of EGF cancer vaccine and the relationship between anti-EGF response and survival of advanced NSCLC patients. No significant financial relationships to disclose." @default.
- W2247275532 created "2016-06-24" @default.
- W2247275532 creator A5001681423 @default.
- W2247275532 creator A5002029328 @default.
- W2247275532 creator A5022492026 @default.
- W2247275532 creator A5031819044 @default.
- W2247275532 creator A5042963282 @default.
- W2247275532 creator A5068435420 @default.
- W2247275532 creator A5070534105 @default.
- W2247275532 creator A5082455874 @default.
- W2247275532 creator A5089147165 @default.
- W2247275532 creator A5091661570 @default.
- W2247275532 date "2004-07-15" @default.
- W2247275532 modified "2023-10-15" @default.
- W2247275532 title "Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial" @default.
- W2247275532 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.2514" @default.
- W2247275532 hasPublicationYear "2004" @default.
- W2247275532 type Work @default.
- W2247275532 sameAs 2247275532 @default.
- W2247275532 citedByCount "2" @default.
- W2247275532 crossrefType "journal-article" @default.
- W2247275532 hasAuthorship W2247275532A5001681423 @default.
- W2247275532 hasAuthorship W2247275532A5002029328 @default.
- W2247275532 hasAuthorship W2247275532A5022492026 @default.
- W2247275532 hasAuthorship W2247275532A5031819044 @default.
- W2247275532 hasAuthorship W2247275532A5042963282 @default.
- W2247275532 hasAuthorship W2247275532A5068435420 @default.
- W2247275532 hasAuthorship W2247275532A5070534105 @default.
- W2247275532 hasAuthorship W2247275532A5082455874 @default.
- W2247275532 hasAuthorship W2247275532A5089147165 @default.
- W2247275532 hasAuthorship W2247275532A5091661570 @default.
- W2247275532 hasConcept C121608353 @default.
- W2247275532 hasConcept C126322002 @default.
- W2247275532 hasConcept C143998085 @default.
- W2247275532 hasConcept C159654299 @default.
- W2247275532 hasConcept C168563851 @default.
- W2247275532 hasConcept C170493617 @default.
- W2247275532 hasConcept C203014093 @default.
- W2247275532 hasConcept C22070199 @default.
- W2247275532 hasConcept C22889606 @default.
- W2247275532 hasConcept C2776256026 @default.
- W2247275532 hasConcept C2776362946 @default.
- W2247275532 hasConcept C2777451964 @default.
- W2247275532 hasConcept C2777701055 @default.
- W2247275532 hasConcept C32611913 @default.
- W2247275532 hasConcept C71924100 @default.
- W2247275532 hasConcept C90924648 @default.
- W2247275532 hasConceptScore W2247275532C121608353 @default.
- W2247275532 hasConceptScore W2247275532C126322002 @default.
- W2247275532 hasConceptScore W2247275532C143998085 @default.
- W2247275532 hasConceptScore W2247275532C159654299 @default.
- W2247275532 hasConceptScore W2247275532C168563851 @default.
- W2247275532 hasConceptScore W2247275532C170493617 @default.
- W2247275532 hasConceptScore W2247275532C203014093 @default.
- W2247275532 hasConceptScore W2247275532C22070199 @default.
- W2247275532 hasConceptScore W2247275532C22889606 @default.
- W2247275532 hasConceptScore W2247275532C2776256026 @default.
- W2247275532 hasConceptScore W2247275532C2776362946 @default.
- W2247275532 hasConceptScore W2247275532C2777451964 @default.
- W2247275532 hasConceptScore W2247275532C2777701055 @default.
- W2247275532 hasConceptScore W2247275532C32611913 @default.
- W2247275532 hasConceptScore W2247275532C71924100 @default.
- W2247275532 hasConceptScore W2247275532C90924648 @default.
- W2247275532 hasIssue "14_suppl" @default.
- W2247275532 hasLocation W22472755321 @default.
- W2247275532 hasOpenAccess W2247275532 @default.
- W2247275532 hasPrimaryLocation W22472755321 @default.
- W2247275532 hasRelatedWork W1997208432 @default.
- W2247275532 hasRelatedWork W2038899530 @default.
- W2247275532 hasRelatedWork W2114584134 @default.
- W2247275532 hasRelatedWork W2358831769 @default.
- W2247275532 hasRelatedWork W2365431450 @default.
- W2247275532 hasRelatedWork W2381991529 @default.
- W2247275532 hasRelatedWork W2384171498 @default.
- W2247275532 hasRelatedWork W2978725 @default.
- W2247275532 hasRelatedWork W3202566745 @default.
- W2247275532 hasRelatedWork W4312045120 @default.
- W2247275532 hasVolume "22" @default.
- W2247275532 isParatext "false" @default.
- W2247275532 isRetracted "false" @default.
- W2247275532 magId "2247275532" @default.
- W2247275532 workType "article" @default.